Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship
about
The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case reportConversion of psychological stress into cellular stress response: roles of the sigma-1 receptor in the processPotentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptorsSigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptorsSigma-1 receptor enhances neurite elongation of cerebellar granule neurons via TrkB signalingSynthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodentsThe clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperonesBeneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.NMDA antagonists under investigation for the treatment of major depressive disorder.Targeting of NMDA receptors in new treatments for schizophrenia.Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder.Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors.Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases.Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases.Potential role of the sigma-1 receptor chaperone in the beneficial effects of donepezil in dementia with lewy bodiesSigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's diseaseBenefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases.Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice.Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions.Are sigma receptor modulators a weapon against multiple sclerosis disease?The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder.Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants.Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine.Sigma-1 receptor agonist fluvoxamine for delirium in older adults.Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.Mechanisms of ketamine action as an antidepressant.Convergent Mechanisms Underlying Rapid Antidepressant Action.
P2860
Q21203919-821522EE-CD14-4E4E-8F55-53E552892D31Q27023681-6684091C-F03A-4A93-9757-2BF8E93EFF4BQ28729237-1AB5FEEF-10C8-4F97-8024-172D36E6256AQ34362333-E20DC41D-8F92-4EDF-85B1-C25D433A3B0BQ34615051-B2C142FC-7E9A-4AF1-81A3-6875D9D0D368Q35014550-6840EAE9-F52A-4F01-A1AB-ADA25D86D856Q35176885-EBD3DD40-DA0D-41D5-9C78-650E5FDA6F55Q35857645-7ECBE655-147C-4627-99B5-1EAEA76F9D3DQ36466836-8CEA6374-AD4D-47BB-BC99-E6F3421409B3Q36755305-854FE628-FD79-4106-91EE-A61051EAD813Q38211107-F62AB56A-5919-4E56-955D-9FD0FB6FD160Q38223276-E3A72D0D-BE19-4E52-BB12-DCEFED5DFF72Q38766222-4F967191-1440-40DE-9651-6D95F850BE6AQ39852066-464A51CD-306D-4D28-8D6C-479153510349Q40489548-2350EB6A-AC9C-4BCA-AF77-633AA9DA1D2AQ40489578-9F3F920B-87E2-47C9-A4DA-6E817CF710C3Q40597888-01964280-C193-49DB-B949-88AD985C40CCQ41879740-BC44EA06-BB5B-4D3E-86A9-73A0EB715042Q41891428-D7F26973-4E7E-418B-82F3-C26907D0882EQ42091045-84885E68-20FA-48E2-AA27-49930E97B5B4Q42923084-A9A456B6-0078-4613-AC52-EB10D1F5433DQ42932794-68ABC73E-D252-43E2-BEF7-00FE7890F91CQ47596098-705DCDE0-3E27-487B-BC37-6C4C3B15266EQ47980447-9D37AD4B-F02F-4696-AFFD-3DBFFF668568Q48277387-F743B5F6-F961-44C5-A616-7BDCE8BBD276Q48946728-57CD6F96-B7B2-4EE8-A72C-A989A88EE324Q50780949-689DF061-6223-417F-A724-59B418B6FC9CQ51094803-F05B2085-792D-47F9-91ED-97FC3BC074C4Q52658612-4ADD0E7C-2B6D-43DA-A4E2-9A41D55D4AE9Q52667723-E9905C65-E7DD-4EF8-BEB3-FEE63A9A3393
P2860
Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Sigma-1 receptors and selectiv ...... ications of their relationship
@ast
Sigma-1 receptors and selectiv ...... ications of their relationship
@en
Sigma-1 receptors and selectiv ...... ications of their relationship
@nl
type
label
Sigma-1 receptors and selectiv ...... ications of their relationship
@ast
Sigma-1 receptors and selectiv ...... ications of their relationship
@en
Sigma-1 receptors and selectiv ...... ications of their relationship
@nl
prefLabel
Sigma-1 receptors and selectiv ...... ications of their relationship
@ast
Sigma-1 receptors and selectiv ...... ications of their relationship
@en
Sigma-1 receptors and selectiv ...... ications of their relationship
@nl
P1476
Sigma-1 receptors and selectiv ...... ications of their relationship
@en
P2093
Kenji Hashimoto
P304
P356
10.2174/1871524910909030197
P407
P50
P577
2009-09-01T00:00:00Z